UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Overexpression of the Major Vault Transporter Protein Lung-Resistance Protein Predicts Treatment Outcome in Acute Myeloid Leukemia

Blood, 1996-03, Vol.87 (6), p.2464-2469

1996

Volltextzugriff (PDF)

Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML)

Leukemia research, 1996-02, Vol.20 (2), p.175-180

1996

Volltextzugriff (PDF)

Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2258-2263

2008

Volltextzugriff (PDF)

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort

Haematologica (Roma), 2018-04, Vol.103 (4), p.e151-e153

2018

Volltextzugriff (PDF)

Reciprocal influences between maternal language and children's language and cognitive development in low-income families

Journal of child language, 2014-03, Vol.41 (2), p.305-326

2014

Volltextzugriff (PDF)

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

Journal of clinical oncology, 2018-03, Vol.36 (7), p.697-703

2018

Volltextzugriff (PDF)

Phase 2 Trial of Combined Cisplatin, Etoposide, Gemcitabine, and Methylprednisolone (PEGS) in Peripheral T-Cell Non-Hodgkin Lymphoma: Southwest Oncology Group Study S0350

Cancer, 2013-01, Vol.119 (2), p.371-379

2013

Volltextzugriff (PDF)

Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma

The New England journal of medicine, 1998-07, Vol.339 (1), p.21-26

1998

Volltextzugriff (PDF)

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity

Immunity (Cambridge, Mass.), 2020-11, Vol.53 (5), p.925-933.e4

2020

Volltextzugriff (PDF)

Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas

Molecular cancer therapeutics, 2017-10, Vol.16 (10), p.2083-2093

2017

Volltextzugriff (PDF)

57 Inability to Report Platelet Counts Due to Interference of Automated Platelet Counting by Microschistocytes: A Caveat in Severely Ill Patients

American journal of clinical pathology, 2018-01, Vol.149 (suppl_1), p.S25-S25

2018

Volltextzugriff (PDF)

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

Clinical cancer research, 2018-12, Vol.24 (24), p.6150-6159

2018

Volltextzugriff (PDF)

Atlas of Nontumor Pathology: Non-Neoplastic Disorders of Bone Marrow First Series: Fascicle 6

The American journal of surgical pathology, 2009-11, Vol.33 (11), p.1742

Spier, Catherine

2009

Volltextzugriff (PDF)

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Blood, 2015-01, Vol.125 (2), p.236-241

2015

Volltextzugriff (PDF)

Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression

Histology and histopathology, 2024-03, Vol.39 (3), p.319-331

2024

Volltextzugriff (PDF)

Wintrobe's Atlas of Clinical Hematology

The American journal of surgical pathology, 2008-09, Vol.32 (9), p.1428

Spier, Catherine

2008

Volltextzugriff (PDF)

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108

Journal of clinical oncology, 2015-07, Vol.33 (21), p.2399-2404

2015

Volltextzugriff (PDF)

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

Blood advances, 2023-09, Vol.7 (17), p.5082-5090

2023

Volltextzugriff (PDF)

Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T‐cell non‐Hodgkin lymphoma

Cancer, 2013-01, Vol.119 (2), p.371-379

2013

Volltextzugriff (PDF)

Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy

Oncotarget, 2017-11, Vol.8 (59), p.100326-100338

2017

Volltextzugriff (PDF)

Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models

Leukemia & lymphoma, 2015-05, Vol.56 (5), p.1432-1439

2015

Volltextzugriff (PDF)

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016

Journal of clinical oncology, 2013-01, Vol.31 (3), p.314

2013

Volltextzugriff (PDF)

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Blood, 2014-08, Vol.124 (8), p.1259-1265

2014

Volltextzugriff (PDF)

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131 I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

Journal of clinical oncology, 2018-03, Vol.36 (7), p.697-703

2018

Volltextzugriff (PDF)

1 – 25 von 110

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(98)

Publikationsform

Artikel
(108)
Berichte
(1)
Reviews
(1)

Sprache

Englisch
(110)

Erscheinungsjahr

n.n

Thema

Humans
(61)
Life Sciences & Biomedicine
(58)
Science & Technology
(58)
Female
(36)
Biological And Medical Sciences
(35)
Male
(35)
Medical Sciences
(33)
Adult
(30)
Aged
(29)
Middle Aged
(29)
Hematology
(25)
Oncology
(22)
Hematologic And Hematopoietic Diseases
(21)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(20)
Aged, 80 And Over
(17)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Immunohistochemistry
(12)
Prognosis
(12)
Phenotype
(11)
Adolescent
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(30)
Journal Of Clinical Oncology
(12)
Cancer
(6)
Clinical Cancer Research
(3)
Leukemia
(3)
Leukemia & Lymphoma
(3)
Molecular Cancer Therapeutics
(3)
American Journal Of Clinical Pathology
(2)
American Journal Of Hematology
(2)
Cancer Research
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Overexpression of the Major Vault Transporter Protein Lung-Resistance Protein Predicts Treatment Outcome in Acute Myeloid Leukemia

Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML)

Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort

Reciprocal influences between maternal language and children's language and cognitive development in low-income families

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

Phase 2 Trial of Combined Cisplatin, Etoposide, Gemcitabine, and Methylprednisolone (PEGS) in Peripheral T-Cell Non-Hodgkin Lymphoma: Southwest Oncology Group Study S0350

Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity

Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas

57 Inability to Report Platelet Counts Due to Interference of Automated Platelet Counting by Microschistocytes: A Caveat in Severely Ill Patients

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

Atlas of Nontumor Pathology: Non-Neoplastic Disorders of Bone Marrow First Series: Fascicle 6

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project

Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression

Wintrobe's Atlas of Clinical Hematology

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T‐cell non‐Hodgkin lymphoma

Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy

Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131 I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

Suchergebnisse filtern